Background/Aims: The effect of inflammatory skin diseases on pregnancy has been incompletely characterized. We sought to estimate the incidence of pregnancy and pregnancy outcomes among women with inflammatory skin diseases. Methods: Cohort study of women with atopic dermatitis (AD), psoriasis, other inflammatory skin diseases, and comparison group, followed for pregnancies and pregnancy outcomes. Results: There were 3,131 pregnancies among 64,773 woman-years (4.8/100) in women with skin diseases, and 2,592 pregnancies among 59,826 woman-years (4.3/100) in the comparison group. The age-standardized incidence of pregnancy was similar to the comparison group [rate ratio (RR) = 1.2, 95% confidence interval (CI) 1.0–1.4 for AD, RR = 1.1, 95% CI 1.0–1.2 for psoriasis, and RR = 1.1, 95% CI 1.0–1.1 for other]. Spontaneous abortion was also similar to the comparison group (RR = 1.2 for AD, 95% CI 1.0–1.4, RR = 1.1, 95% CI 1.0–1.2 for psoriasis, and RR = 1.1, 95% CI 1.0–1.1 for other). Conclusions: Our results suggest little effect of skin disease on incidence or outcome of pregnancy.

Keywords:
Atopic dermatitis, Pregnancy, Psoriasis
1.
Tofte SJ, Hanifin JM: Current management and therapy of atopic dermatitis. J Am Acad Dermatol 2001;44:S13–S16.
2.
Charman C: Atopic eczema. BMJ 1999;318:1600–1604.
3.
Russell JJ: Topical tacrolimus: a new therapy for atopic dermatitis. Am Fam Phys 2002;66:1899–1902.
4.
Barnetson RSC, Rogers M: Childhood atopic eczema. BMJ 2002;324:1376–1379.
5.
Greaves MW, Weinstein GD: Treatment of psoriasis. N Engl J Med 1995;332:581–588.
6.
Robert C, Kupper TS: Inflammatory skin diseases, T-cells, and immune surveillance. N Engl J Med 1999;341:1817–1828.
7.
Granstein RD: New treatments for psoriasis. N Engl J Med 2001;345:284–287.
8.
Drug Facts and Comparisons. St. Louis, Facts and Comparisons, 2003.
9.
Hultscha T, Kappc A, Spergelb J: Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology 2005;211:174–187.
10.
Tacrolimus (Protopic®) package insert. Deerfield, Fujisawa, 2002.
11.
Ruzicka T, Bieber T, Schopf E, et al: A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med 1997;337:816–821.
12.
Hanifin JM, Ling MR, Langley R, Breneman D, Rafal E: Tacrolimus ointment for the treatment of atopic dermatitis in adult patients. I. Efficacy. J Am Acad Dermatol 2001;44:S28–S38.
13.
Soter NA, Fleischer AB Jr, Webster GF, Monroe E, Lawrence I: Tacrolimus ointment for the treatment of atopic dermatitis in adult patients. II. Safety. J Am Acad Dermatol 2001;44:S39–S46.
14.
Moore MM, Rifas-Shiman SL, Rich-Edwards JW, et al: Perinatal predictors of atopic dermatitis occurring in the first six months of life. Pediatrics 2004;113:468–474.
15.
Raychaudhuri SP, Navare T, Gross T, Raychoudhuri SK: Clinical course of psoriasis during pregnancy. Int J Dermatol 2003;42:518–520.
16.
Rothman KJ: Epidemiology: An Introduction. New York, Oxford University Press, 2002.
17.
STATA: Intercooled Stata 6.0 for Windows. College Station, Stata Corporation, 1999.
18.
Ventura SJ, et al: Revised pregnancy rates, 1990–97, and new rates for 1998–99, United States. National Vital Statistics Reports. Hyattsville, National Center for Health Statistics, vol 52, 2003.
19.
Martin JA, et al: Births: final data for 2001. National Vital Statistics Reports. Hyattsville, National Center for Health Statistics, vol 51, 2002.
© 2007 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.